SARAH STORR sarah.storr@nottingham.ac.uk
Assistant Professor
A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease
Storr, Sarah J.; Hoskin, Victoria; Aiyappa‐Maudsley, Radhika; Ghaffari, Abdi; Varma, Sonal; Green, Andrew; Rakha, Emad; Ellis, Ian O.; Greer, Peter A.; Martin, Stewart G.
Authors
Victoria Hoskin
Radhika Aiyappa‐Maudsley
Abdi Ghaffari
Sonal Varma
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Ian O. Ellis
Peter A. Greer
STEWART MARTIN STEWART.MARTIN@NOTTINGHAM.AC.UK
Professor of Cancer and Radiation Biology
Abstract
Introduction: The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studies to date have been conducted in smaller cohorts (less than 500 cases) or have focused on specific disease characteristics. The current study is the largest of its kind to evaluate ezrin both at the protein and mRNA levels in early-stage breast cancer patients using the Nottingham (n=1094) and METABRIC (n=1980) cohorts, respectively. Results: High expression of ezrin was significantly associated with larger tumour size (p=0.027), higher tumour grade (p < 0.001), worse Nottingham Prognostic Index prognostic group (p=0.011) and HER2-positive status (p=0.001). High ezrin expression was significantly associated with adverse survival of breast cancer patients (p < 0.001) and remained associated with survival in multivariate Cox-regression analysis (p=0.018, hazard ratio (HR)=1.343, 95% confidence interval (CI)=1.051–1.716) when potentially confounding factors were included. High ezrin expression was significantly associated with adverse survival of patients whose tumours were categorised as receptor (oestrogen receptor (ER), progesterone receptor (PgR) or HER2) positive (p < 0.001) in comparison to those categorised as triple-negative breast cancer (p=0.889). High expression of ezrin mRNA (VIL2) in the METABRIC cohort was also significantly associated with adverse survival of breast cancer patients (p < 0.001). Conclusion: Retrospective analyses show that ezrin is an independent prognostic marker, with higher expression associated with shortened survival in receptor-positive (ER, PgR or HER2) patients. Ezrin expression is associated with more aggressive disease and may have clinical utility as a biomarker of patient prognosis in early-stage breast cancer.
Citation
Storr, S. J., Hoskin, V., Aiyappa‐Maudsley, R., Ghaffari, A., Varma, S., Green, A., …Martin, S. G. (2023). A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease. Cancer Medicine, 12(9), 10908-10916. https://doi.org/10.1002/cam4.5802
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 27, 2023 |
Online Publication Date | Mar 20, 2023 |
Publication Date | 2023-05 |
Deposit Date | May 16, 2023 |
Publicly Available Date | May 19, 2023 |
Journal | Cancer Medicine |
Electronic ISSN | 2045-7634 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 12 |
Issue | 9 |
Pages | 10908-10916 |
DOI | https://doi.org/10.1002/cam4.5802 |
Keywords | Breast cancer, EZR, ezrin, VIL2 |
Public URL | https://nottingham-repository.worktribe.com/output/18804840 |
Publisher URL | https://onlinelibrary.wiley.com/doi/10.1002/cam4.5802 |
Additional Information | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited |
Files
mRNA expression in breast cancer
(2.7 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Multiple pathways regulate Cten in colorectal cancer without a Tensin switch.
(2015)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search